Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Designating an Orphan Product: Drugs and Biological Products

Designating an Orphan Product: Drugs and Biological Products

                        Orphan Drug Designation Request Form
          Orphan Drug Act - Relevant Excerpts
          Frequently Asked Questions (FAQ) About Designating an Orphan Product
          Orphan Drug Designation: Disease Considerations
          Clinical Superiority Findings
          Instructions for Searchable Designation Database
          Public Identification of Orphan Drug Designation
          Improving the Prevention, Diagnosis, and Treatment of Rare and Neglected Diseases; FDA Report to Congress
          Contact Us Home
          For Industry
          Medical products for rare diseases and conditions
          Designating an Orphan Product: Drugs and Biological Products
          Frequently Asked Questions (FAQ) About Designating an Orphan ProductDesignating an Orphan Product: Drugs and Biological Products Frequently Asked Questions (FAQ) About Designating an Orphan Product
  
  	
    Share
    Post
    Linkedin

    Email
    PrintSponsors seeking orphan drug designation for a drug or biological product must submit a request for designation to the agency. Designation is given to a drug or biologic for the treatment, diagnosis or prevention of a rare disease or condition. See below for frequently asked questions about submitting requests for orphan drug designation.

FAQ# 1 - Does the contact person’s signature need to be on the cover letter of the orphan drug designation request? Can a signature page be sent separately?
	An original signature of an individual representing the sponsor organization is required on one copy of the orphan drug designation request (typically the cover letter.) The original signature does not have to be the contact person. For example, the sponsor’s CEO may sign the cover letter, but the individual listed as the contact person is the head of regulatory affairs.

FAQ# 2 - Can the orphan drug designation request be submitted electronically? What is required?
	Yes. Orphan drug requests can be submitted by email to orphan@fda.hhs.gov. Please include a dated and signed cover letter, a bibliography and full copies (not abstracts) of all references cited. See Designating an Orphan Product: Drugs and Biological Products for more information.

FAQ# 3 - What information about orphan drug designations is publicly available? What if the sponsor does not provide a generic and trade name of the drug?
	If a product receives an orphan drug designation, certain information (sponsor’s name, address and contact information, name of drug, orphan designated use and date of designation and status) about the orphan designated product will be available in the FDA’s searchable database.

FDA will post the generic and trade name of the drug, or if neither is available, the chemical name or a meaningful descriptive name of the drug provided by the sponsor and subject to approval by FDA. See 21CFR 316.28(b) for more information.

If a designated product is approved by FDA for marketing, certain additional information is available on the website (approval date, approved indication and exclusivity status).

FAQ# 4 - What is the review process once the orphan drug designation request is received by FDA?
	The FDA will send an acknowledgement letter to the sponsor (or sponsor’s agent). The FDA conducts the review of the request, which may require agency-wide coordination. When FDA’s review of the request is complete, if FDA determines the drug is eligible for orphan drug designation, FDA will send the sponsor a designation letter. The sponsor may receive a deficiency letter requesting additional information or a denial letter as appropriate.

FAQ# 5 - The regulations say that the sponsor is required to submit all relevant data about their drug in the orphan drug designation request. Why doesn’t the sponsor have to submit animal toxicology data in the orphan drug designation request?
	In order to designate a product as an orphan drug, the scientific rationale portion of the designation application must include enough information to establish a medically plausible basis for expecting the drug to be effective in the rare disease. The scientific rationale is best supported by clinical data of the drug in treating, preventing or diagnosing the rare disease. However, in the absence of human data, the application for orphan drug designation may be satisfactorily supported with preclinical data using the drug in a relevant animal model for the human disease.

In the absence of human data and when a relevant animal model does not exist, the FDA may consider a combination of alternative data that includes the pathogenesis of the disease, a clear description of the drug and its mechanism of action specific to the disease and supporting in vitro data.

Animal toxicology data describing the safety of the drug in animals do not provide efficacy data and are not generally relevant in supporting the scientific rationale. Only in rare situations, where there is an absence of both human data and a relevant in vivo model, will FDA consider a combination of alternative data that include the pathogenesis of the disease, a clear description of the drug and its mechanism of action specific to the disease and supporting in vitro data.

FAQ# 6 - What information is required for an orphan drug designation request?
	See Recommended Tips for Creating an Orphan Drug Designation Application for information on compiling an orphan drug designation request.

FAQ# 7 - If the sponsor is from a foreign country, is a U.S. agent required to file a designation request?
	A sponsor located outside the U.S. is required to have a U.S. permanent resident agent to file a request for an orphan drug designation. All correspondence to and from FDA related to international sponsors should go through the U.S. agent including submitting annual reports after a product is designated as an orphan drug.

A U.S. agent can be anyone residing in the U.S. who is responsible for the paperwork involved with the designation request and, if a designation is granted, will serve as the primary contact going forward. If the sponsor’s U.S. agent changes, FDA must be notified.

FAQ# 8 - What if the sponsor has difficulty finding data on prevalence? In the case of a product used for an acute condition, should incidence of fewer than 200,000 people be used instead of prevalence?
	Besides referenced texts and journals, prevalence data for many rare diseases can be found on the internet at government and patient support group websites. There is no general list of specific conditions considered to have prevalence of fewer than 200,000. Copies of all materials documenting how the prevalence estimate was determined should be provided in the designation request. If the reference source is from a website, a hard copy of the document should be included as well as the website address. The date each website was accessed should also be provided for all website sources referenced.

Sponsors are expected to make a good faith effort in finding the most recent prevalence data that refers to a United States population. If only old and/or foreign data are available, the sponsor should explain this in the request. If data are old, the sponsor should explain why the data are still pertinent and, if from a foreign source, why data from that country’s population could also be representative of U.S. population.

The prevalence estimate must be current to reflect the prevalence at the time of submission of the request for orphan drug designation (21CFR 316.21 (b)). To update this estimate, the sponsor should use U.S. population data available from the U.S. Census Bureau.

Provide all calculations and cite references used to make the population estimate. The estimate should be current at the time of the submission of the orphan drug designation request. U.S. Census Bureau data can be used to update any population estimate.

When a range of estimates exists, FDA accepts only the largest estimate unless a justification is provided why another estimate is more accurate.

If the drug is intended for diagnosis or prevention of a rare disease or condition, provide the estimated number of people to whom the drug will be administered annually.

If a disease is an acute condition (e.g., less than one year duration) incidence may be used as an estimate of the population. However, note that if the disease is a relapsing/remitting disease where each episode is acute in duration, a prevalence estimate may still be required.

If using data from a claims database or foreign data, clearly explain how such data are generalizable to the U.S. population and the limitations of the data.

The National Cancer Institute’s Surveillance, Epidemiology and End Results Program is one recommended resource for determining cancer statistics in the United States.

FAQ# 9 - If the intended designated use of a drug is for prevention rather than treatment, how is the population estimated in each case?
	If the drug is being used for prevention, the population estimate should be the number of people to whom the drug will be administered annually in the U.S. (21 CFR 316.21(b)(3).)

FAQ# 10 - Under what conditions will FDA designate an orphan drug and recognize orphan drug exclusivity for a new formulation of a drug that is otherwise the same as an approved drug for the same rare disease or condition?
	The public policy objective of the Orphan Drug Act is to stimulate innovation in developing treatments for patients with rare diseases and conditions, and to foster the prompt availability of clinically superior drugs. Accordingly, FDA’s regulations help ensure orphan drug exclusivity does not preclude significant improvements in treating rare diseases.

FDA may grant orphan drug designation to a drug that is otherwise the same drug as a drug already approved in the U.S. for the same rare disease or condition only if the sponsor can present a plausible hypothesis that its drug may be clinically superior to the previously approved drug. See 21 CFR 316.20(a) for more information.

Clinical superiority may be established by means of greater effectiveness, greater safety in a substantial portion of the target populations, or in unusual cases a major contribution to patient care. (21 CFR 316.3(b)(3).)

If orphan drug designation is granted, and if the drug receives marketing approval for the designated use, in order for the drug to be eligible for orphan drug exclusivity, the sponsor must demonstrate that the drug is clinically superior to any previously approved same drug for the same use (21 CFR 316.34(c).) Any claim for clinical superiority could require a head-to-head trial.

FAQ# 11 - What does FDA consider a major contribution to patient care?
	The following factors, when applicable to severe or life-threatening diseases, may in appropriate cases be taken into consideration when determining whether a drug makes a major contribution to patient care:

Convenient treatment location
	Duration of treatment
	Patient comfort
	Reduced treatment burden
	Advances in ease and comfort of drug administration
	Longer periods between doses
	Potential for self-administrationFactors that FDA cannot consider when determining whether a drug makes a major contribution to patient care include:

Cost of therapy
	Compliance to therapy (significantly improved compliance should be reflected by a measure of greater safety or efficacy)

FAQ# 12 - Please explain orphan subset.
	Sponsors can receive orphan drug designation for the use of a drug in an orphan subset of a non-rare disease or condition when they can explain based on a characteristic or feature of the drug why the drug will be limited to use in an orphan subset of a non-rare disease. An orphan subset is not based on an unmet need, or how a sponsor may wish to study or indicate a drug. The explanation for the orphan subset must make it clear that the drug could never be used in the disease or condition outside of the subset. See 21 CFR 316.3(b)(13) for more information.

FAQ# 13 - If changes are made to the product formulation after receiving orphan designation and prior to NDA submission, will the approved NDA still qualify for exclusivity?
	Orphan drug designation is generally granted to the active moiety rather than the product formulation so changes to the product formulation should not generally affect orphan drug designation status.
The first sponsor to bring an active moiety to market for a particular use or indication is generally eligible for orphan drug exclusivity if that sponsor has orphan designation for that drug. If the sponsor subsequently makes a change in formulation to the original product, which was designated and approved for marketing, we consider the sponsor to still have designation for the active moiety. The sponsor will not be eligible for a new term of orphan drug exclusivity upon approval of the changed formulation unless the sponsor can demonstrate that the changed formulation is clinically superior to the original approved product.

**Contact**
Contact orphan@fda.hhs.gov with questions.

Additional Resources:

Webinar: Recommended Tips for Creating an Orphan Drug Designation Application

	Webinar slides
		Webinar script

                                                                                  Content current as of:
      05/11/2023Designating an Orphan Product: Drugs and Biological Products

          
                        Orphan Drug Designation Request Form
          Orphan Drug Act - Relevant Excerpts
          Frequently Asked Questions (FAQ) About Designating an Orphan Product
          Orphan Drug Designation: Disease Considerations
          Clinical Superiority Findings
          Instructions for Searchable Designation Database
          Public Identification of Orphan Drug Designation
          Improving the Prevention, Diagnosis, and Treatment of Rare and Neglected Diseases; FDA Report to Congress
          Contact Us
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop